Ribon Therapeutics

Recent Finacing

Equity

Recent Raise

$25M

Ribon Therapeutics is a clinical-stage biotech developing selective small-molecule inhibitors of stress-activated NAD+-utilizing enzymes (monoPARPs) via its BEACON+ platform, advancing PARP7 and PARP14 programs for oncology and inflammation.

Founded 2015

Massachusetts, United States

11-50

Private

ribontx.com

Highlights

Focus Areas

Biotechnology

Health Care

Medical Device

Therapeutics

Recent Investors

E

A

Financials

$155M

Total Raised

3

Funding rounds

16

Investors

Team

Upgrade to view the team

See the team members at Ribon Therapeutics.